OBJECTIVE
Laboratory services are a mandatory Medicaid benefit under Federal law and regulations. Federal regulations require laboratory services to be ordered by a physician or other practitioner and performed by a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified laboratory (42 CFR 440.30 (a) and (c)). Drug testing is the process of using a biological sample (e.g., urine or blood) to detect the presence or absence of a drug or its metabolites in the body. Generally, there are two types of drug testing services: presumptive and definitive. Definitive drug testing is used when greater analytical specificity is necessary and has a higher reimbursement rate than presumptive drug testing, which simply indicates a presence or absence of the drug or its metabolite in the body. Laboratories bill for definitive drug testing based on the number of drug classes being tested. Prior OIG audits and CMS reports have identified risks of overpayments for the highest definitive drug testing code (procedure code G0483) in Medicare. We will review whether selected States’ Medicaid fee-for-service payments to laboratories for definitive drug testing services complied with Federal and State requirements.
There is 1 project in this series.
ACTIVE PROJECTS IN THIS SERIES (1)
Audit of Medicaid Fee-for-Service Payments for Drug Testing Services
TIMELINE
-
November 5, 2026Series Number SRS-A-27-005 Assigned
-
November 5, 2026Project Announced
Audit of Medicaid Fee-for-Service Payments for Drug Testing Services - OAS-26-09-080
-
Today1 Audit In-Progress
-
Est FY2028Estimated Fiscal Year for Series Completion